Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Amedisys, Inc." (AMED) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Amedisys, Inc." (AMED)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Health Care Providers & Services
Competitors: AFAM, AHS, DRAD, CHE

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: B down no change
Last Week: B same downgrade
Two Weeks Ago: A up upgrade
service keys

"Amedisys, Inc."© quotemedia

Company Profile

Amedisys, Inc., a health care company, provides home health and hospice services primarily in the United States. It operates in two segments, Home Health and Hospice. The Home Health segment offers various services in the homes of individuals who may be recovering from an illness, injury, or surgical procedure. This segment’s services include skilled nursing, home health aides, physical and occupational therapy, speech therapy, and medical social services; and chronic care clinical programs for patients with chronic diseases, such as cardiovascular, respiratory, diabetes, behavioral health, rehabilitative, and medical surgical conditions. The Hospice segment provides care that is designed to offer comfort and support for those who are facing a terminal illness, such as heart disease, pulmonary disease, dementia, Alzheimer’s, HIV/AIDS, or cancer. As of December 31, 2011, the company owned and operated 440 Medicare-certified home health care centers, 87 Medicare-certified hospice care centers, and 2 hospice inpatient units in 41 states within the United States, the District of Columbia, and Puerto Rico. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Recent News: "Amedisys, Inc."